Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: Results of an effectiveness study

Archives of Ophthalmology

Volumn 122, Issue 6, 2004, Pages 853-856

  Sharma, Sanjay ^a,b   Bakal, Jeff ^a,b   Oliver Fernandez, Alejandro ^b   Blair, Jason ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b HOTEL DIEU HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; COVARIANCE; DIPLOPIA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEARING LOSS; HUMAN; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOVEA CENTRALIS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 2942536631     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.6.853     Document Type: Article

References (22)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
2. Mackenzie PJ, Chang TS, Scott IU, et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology. 2002;109:720-729.
3. Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481-484.
4. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32:375-413.
5. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500-509.
6. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189-1199.
7. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
8. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1232-1241.
9. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the Macular Photocoagulation Study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol. 1995;113:185-189.
10. Gelfand YA, Linn S, Miller B. The application of the Macular Photocoagulation Study eligibility criteria for laser treatment in age-related macular degeneration. Ophthalmic Surg Lasers. 1997;28:823-827.
11. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112:480-488.
12. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
13. commercial, approval status page. QLTInc Web site. Available at: http: //www.qltinc.com/Qltinc/mainhome.cfm. Accessed January 22, 2004.
14. Sharma S. Levels of evidence and interventional ophthalmology. Can J Ophthalmol. 1997;32:359-362.
15. Health outcomes methodology. Med Care. 2000;38(9 suppl):II7-II13.
16. Freund D, Lave J, Clancy C, et al. Patient Outcomes Research Teams: contribution to outcomes and effectiveness research. Annu Rev Public Health. 1999;20:337-359.
17. D'Agostino RB, Kwan H. Measuring effectiveness: what to expect without a randomized control group. Med Care. 1995;33(suppl 4):AS95-AS105.
18. Kupfer C. The expanded role of randomized clinical trials. Am J Ophthalmol. 1996;122:883-885.
19. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001;108:2051-2059.
20. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol. 2001;36:332-338.
21. Kupfer C. Outcomes research: translating efficacy into effectiveness. Optom Vis Sci. 1998;75:235-236.
22. Cohen SJ. Efficacy, effectiveness, and sustainability: translating research into improvements in health care. Med Care. 2000;38:449-450.